Home›Infectious Disease› Vonoprazan-amoxicillin dual therapy is a safe alternative to bismuth-containing quadruple therapy for H. pylori
Vonoprazan-amoxicillin dual therapy is a safe alternative to bismuth-containing quadruple therapy for H. pyloriNew vonoprazan treatments show promise for clearing H. pylori infection
Frontiers in MedicinePublished July 5, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider vonoprazan-amoxicillin dual therapy as a simplified, safe alternative to bismuth-containing quadruple therapy.
This multicenter, open-label, randomized controlled trial evaluated three treatment regimens for H. pylori eradication in 579 H. pylori-positive patients: VBQ (vonoprazan, amoxicillin, doxycycline, and bismuth), VA (vonoprazan and amoxicillin), and VD (vonoprazan and doxycycline).
Primary outcomes showed that VA demonstrated non-inferiority to VBQ in eradication rates. For the VD group, while the ITT analysis did not meet the non-inferiority criterion (79.3% vs. 83.4%, P = 0.070), both the mITT analysis (87.4% vs. 90.4%, P = 0.018) and PP analysis (87.7% vs. 90.1%, P = 0.012) demonstrated non-inferiority to VBQ.
Regarding safety, the incidence of adverse events was not significantly different between VBQ and VA (P = 0.313), while it was significantly lower in the VD group compared to VBQ (P = 0.002). Medication adherence showed no statistically significant differences between VA and VBQ (P = 0.381) or between VD and VBQ (P = 0.269).
A primary limitation of this study is that data on doxycycline in this specific context are scarce. Clinically, vonoprazan-amoxicillin dual therapy may serve as a simpler alternative to quadruple therapy, while vonoprazan-doxycycline dual therapy may be considered for patients with amoxicillin allergies.
How this fits prior evidence
How this fits prior evidence: This study addresses the challenge of H. pylori treatment failure driven by antibiotic resistance mutations in the Asia-Pacific region. While susceptibility-guided sequential therapy showed no superiority over empirical therapy, these results suggest that vonoprazan-based dual therapies (VA and VD) provide viable alternatives to traditional bismuth-containing quadruple therapy for eradication.
Living with an H. pylori infection can be a hurdle for digestive health. While many people currently use complex treatments involving four different ingredients to clear the bacteria, researchers are looking at ways to simplify the process without losing effectiveness.
A study of 579 patients compared three different treatment paths. One was a standard quadruple therapy containing bismuth. The others were simpler dual therapies: one using vonoprazan and amoxicillin, and another using vonoprazan and doxycycline. The results showed that the two-drug amoxicillin mix worked just as well as the four-drug version for clearing the infection.
The study also looked at a vonoprazan and doxycycline combination. While some data points were mixed, specific analyses suggested this pair is an effective option, especially for patients who cannot take amoxicillin due to allergies. Both simpler options showed similar levels of patient adherence to the medication. Because data on doxycycline in this specific context are still limited, these findings offer a promising path toward simpler treatment plans.
What this means for you:
Simpler two-drug combinations can be as effective as complex four-drug treatments for clearing H. pylori.
Common questions
Are these new treatments as effective as the standard four-drug therapy?
Yes, the study found that a two-drug combination of vonoprazan and amoxicillin was not inferior to the standard quadruple therapy containing bismuth. This means it worked just as well at clearing the H. pylori infection while being a simpler regimen for the patient.
Is there an option for patients allergic to amoxicillin?
Yes, a combination of vonoprazan and doxycycline was shown to have acceptable efficacy. This specific pair may be a good consideration for patients who cannot take amoxicillin due to allergies.
Are these simpler treatments safe to use?
The study found that the number of adverse events was not significantly different between the vonoprazan-amoxicillin and the quadruple therapy. The vonoprazan-doxycycline group actually reported significantly fewer adverse events compared to the quadruple therapy.
BackgroundBismuth-containing quadruple therapy, the standard Helicobacter pylori (H. pylori) eradication regimen, is limited by adverse events and rising resistance. Vonoprazan-amoxicillin dual therapy offers simplicity but has mostly been tested using high-dose amoxicillin. Data on doxycycline in this context are scarce, and vonoprazan-doxycycline dual therapy remains unexplored.MethodsA total of 579 H. pylori-positive patients were enrolled and randomly assigned in a 1:1:1 ratio to one of three 14-day treatment groups: the VBQ group (vonoprazan 20 mg, amoxicillin 1000 mg, doxycycline 100 mg, and colloidal bismuth pectin 300 mg, all twice daily); the VA group (vonoprazan 20 mg and amoxicillin 1000 mg, twice daily); and the VD group (vonoprazan 20 mg and doxycycline 100 mg, twice daily). A 13C-urea breath test (UBT) was performed at least four weeks after treatment completion. H. pylori eradication rates, the incidence of adverse events during treatment, and medication adherence were compared among the three groups.ResultsIn the intention-to-treat (ITT), modified intention-to-treat (mITT), and per-protocol (PP) analyses, the VA regimen demonstrated non-inferiority to the VBQ regimen. The VD regimen did not meet the non-inferiority criterion in the ITT analysis (79.3% vs. 83.4%, P = 0.070 for non-inferiority), but it demonstrated non-inferiority to the VBQ regimen in both the mITT (87.4% vs. 90.4%, P = 0.018) and PP (87.7% vs. 90.1%, P = 0.012) analyses. The overall incidence of adverse events was not significantly different between the VBQ and VA groups (P = 0.313), but it was significantly lower in the VD group compared to the VBQ group (P = 0.002). No statistically significant differences in medication adherence were observed between the VBQ group and either the VA (P = 0.381) or VD (P = 0.269) group.ConclusionVonoprazan-low-dose amoxicillin dual therapy is a safe and simple alternative to bismuth containing quadruple therapy. Vonoprazan-doxycycline dual therapy demonstrates acceptable efficacy and may be considered for patients allergic to amoxicillin. Both align with antimicrobial stewardship principles of regimen simplification.
